{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:25:08Z","timestamp":1786998308744,"version":"build-2736575974"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Foundation for Gynecologic Oncology Improving Outcomes in Gynecologic Oncology Patients"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ygyno.2018.09.014","type":"journal-article","created":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T06:59:45Z","timestamp":1538290785000},"page":"501-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3409-583X","authenticated-orcid":false,"given":"Adam C.","family":"ElNaggar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erinn M.","family":"Hade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret I.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-0966","authenticated-orcid":false,"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor J.","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2018.09.014_bb0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0002-9378(80)90024-1","article-title":"The role of adjuvant therapy in Stage I ovarian cancer","volume":"138","author":"Hreshchyshyn","year":"1980","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.09.014_bb0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/95.2.113","article-title":"International collaborative ovarian neoplasm trial 1 and adjuvant ChemoTherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma","volume":"95","author":"Trimbos","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"22","key":"10.1016\/j.ygyno.2018.09.014_bb0015","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1001\/jama.2011.749","article-title":"Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis","volume":"305","author":"Biagi","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ygyno.2018.09.014_bb0020","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1006\/gyno.2002.6750","article-title":"Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?","volume":"86","author":"Flynn","year":"2002","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.09.014_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2013.07.086","article-title":"The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study","volume":"131","author":"Hofstetter","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.09.014_bb0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2012.07.023","article-title":"Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials","volume":"49","author":"Mahner","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2018.09.014_bb0035","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ygyno.2014.04.004","article-title":"Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?","volume":"133","author":"Lydiksen","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.09.014_bb0040","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2005.03.065","article-title":"Relationship between time interval from primary surgery to the start of taxane-plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study","volume":"23","author":"Gadducci","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.09.014_bb0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2006.01.035","article-title":"Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer","volume":"102","author":"Paulsen","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.09.014_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2013.02.010","article-title":"We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies","volume":"129","author":"Alvarez","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.09.014_bb0055","author":"Quality Measures"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818312332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818312332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T22:47:42Z","timestamp":1545259662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818312332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0090825818312332"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.09.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}